THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 118 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2021. The put-call ratio across all filers is 7.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $120,725 | -17.9% | 13,989 | -1.5% | 0.00% | 0.0% |
| Q2 2023 | $147,042 | -7.4% | 14,207 | -3.0% | 0.00% | 0.0% |
| Q1 2023 | $158,844 | -12.5% | 14,640 | -9.5% | 0.00% | -50.0% |
| Q4 2022 | $181,472 | +15.6% | 16,174 | +4.3% | 0.00% | 0.0% |
| Q3 2022 | $157,000 | +15.4% | 15,513 | +3.6% | 0.00% | +100.0% |
| Q2 2022 | $136,000 | -4.9% | 14,979 | +0.3% | 0.00% | 0.0% |
| Q1 2022 | $143,000 | -12.8% | 14,941 | +0.7% | 0.00% | 0.0% |
| Q4 2021 | $164,000 | +50.5% | 14,831 | +0.9% | 0.00% | 0.0% |
| Q3 2021 | $109,000 | -38.4% | 14,705 | +20.8% | 0.00% | 0.0% |
| Q2 2021 | $177,000 | -33.5% | 12,174 | -6.6% | 0.00% | -50.0% |
| Q1 2021 | $266,000 | +16.2% | 13,038 | +1.1% | 0.00% | 0.0% |
| Q4 2020 | $229,000 | +16.2% | 12,894 | -3.2% | 0.00% | 0.0% |
| Q3 2020 | $197,000 | -4.8% | 13,325 | +34.9% | 0.00% | -33.3% |
| Q2 2020 | $207,000 | -10.4% | 9,878 | -1.2% | 0.00% | -25.0% |
| Q1 2020 | $231,000 | – | 9,994 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,012,226 | $60,515,510 | 8.59% |
| Irenic Capital Management LP | 2,760,948 | $23,826,981 | 6.76% |
| Newtyn Management, LLC | 1,841,560 | $15,892,663 | 3.92% |
| Weiss Asset Management LP | 7,457,060 | $64,354,428 | 3.81% |
| Park West Asset Management LLC | 1,983,251 | $17,115,456 | 1.57% |
| Baupost Group | 7,419,226 | $64,028 | 1.23% |
| Oasis Management Co Ltd. | 953,254 | $8,226,582 | 0.36% |
| Chescapmanager LLC | 287,333 | $2,479,684 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 325,985 | $2,813 | 0.24% |
| Virtus ETF Advisers LLC | 29,232 | $252,272 | 0.15% |